Stockscreener 앱 받기
74.96
3.20%
2.325
시간 외 거래:
75.09
0.13
+0.17%
전일 마감가:
$72.64
열려 있는:
$72.96
하루 거래량:
2.83M
Relative Volume:
1.71
시가총액:
$8.89B
수익:
$1.51B
순이익/손실:
$348.84M
주가수익비율:
26.96
EPS:
2.7805
순현금흐름:
$667.65M
1주 성능:
+9.35%
1개월 성능:
+9.08%
6개월 성능:
+8.84%
1년 성능:
+42.70%
1일 변동 폭
$72.71
$76.32
1주일 범위
$68.27
$76.32
52주 변동 폭
$51.06
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
74.96 | 8.89B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO) - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (DUS:RV7) - TradingView
Halozyme Therapeutics Inc (HALO) Institutional Confidence - TradingKey
Halozyme Therapeutics, Inc. Actuals & Estimates (FWB:RV7) - TradingView
HALO Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
RV7 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Enterprise value to revenue forward of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView
Price to earnings forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection - GlobeNewswire Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 22% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Halozyme Therapeutics Inc (HALO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics Inc (HALO) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders - Sahm
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment - Sahm
Halozyme Therapeutics Inc (HALO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Halozyme Therapeutics Inc (HALO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Halozyme Therapeutics Inc (HALO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Halozyme Therapeutics Inc (HALO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Halozyme (HALO) CLO reports RSU vesting and share withholding for taxes - Stock Titan
Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93 - Moomoo
(HALO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Halozyme Therapeutics Expects Proposed Rule to Have Little Impact on Royalties - marketscreener.com
Halozyme sees minimal impact from Medicare drug pricing rule - Investing.com
Halozyme sees minimal impact from Medicare drug pricing rule By Investing.com - Investing.com Australia
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a 20% Upside Potential - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) up 0.8% since last earnings report: Can it continue? - MSN
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering a 17.29% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Natixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
TD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Halozyme Therapeutics (HALO) Gains 2.76% as Shares Approach Key ResistanceMA Crossover - newsline.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):